Using an mTOR inhibitor, namely Torin2, which is a selective mTORC1 inhibitor, was also shown to restore sensitivity to crizotinib in ALK-mutated (ALKF1174L) NB cells [28,69]. The gene discussed is ALK; the disease is neuroblastoma.